Neuroprotective Products Market Overview
The Neuroprotective Products Market size is estimated to reach $28.3 billion by 2028, growing at a CAGR of 6.9% during the forecast period 2023-2028. The increasing application of neuroprotective products in the treatment of numerous central nervous system complexities like Alzheimer’s Disease that requires cholinesterase inhibitors is set to drive the Neuroprotective Products Market. According to Alzheimer's Association, an estimated 6.5 million Americans, aged 65 and older, are living with Alzheimer's in 2022 and this number is projected to reach 12.7 million by 2050. The growing R&D activities in the healthcare sector are set to propel the growth of the Neuroprotective Products Industry during the forecast period 2023-2028. NMDA receptor antagonists were the first class of therapeutic agents for acute stroke to advance from development in the laboratory to testing in humans. Managing neurotrophic factors could depict a substitute strategy for the treatment of acute and chronic brain ailments. Acute or chronic neurodegenerative ailments depict superior targets for performing techniques involving metal ion chelators. Ion channel modulators have been tested as neuroprotective therapies. This represents the Neuroprotective Products Industry Outlook.
Neuroprotective Products Market Report Coverage
The “Neuroprotective Products Market Report - Forecast (2023-2028)” by IndustryARC, covers an in-depth analysis of the following segments in the Neuroprotective Products Market.
By Medical Condition: Alzheimer’s Disease, Parkinson’s
Disease, Spinal Cord Injury, Stroke and Others.
By Drug Class: Cholinesterase Inhibitors, NMDA Receptor Antagonists, Neurotropic Factors, Metal Ion Chelators, Ion Channel Modulators and Others.
By Geography: North America (the US, Canada and Mexico), Europe (Germany, France, the UK, Italy, Spain, Russia and the Rest of Europe), Asia-Pacific (China, Japan, South Korea, India, Australia & New Zealand and the Rest of Asia-Pacific), South America (Brazil, Argentina, Chile, Colombia and the Rest of South America) and the Rest of the World (the Middle East and Africa).
- Geographically, Europe (Neuroprotective Products market share) accounted for the highest revenue share in 2022 and it is poised to dominate the market over the period 2023-2028. This is due to the massive number of geriatric inhabitants requiring cholinesterase inhibitors in the European region.
- The growth of the Neuroprotective Products Market is being driven by the growing application of neuroprotective products including cholinesterase inhibitors. However, advantageous motor and sensory recovery after peripheral nerve injury is a clinical challenge and is one of the major factors hampering the growth of the Neuroprotective Products Market.
- Neuroprotective Products Market Detailed Analysis of the Strengths, Weaknesses and Opportunities of the prominent players operating in the market would be provided in the Neuroprotective Products Market report.
Neuroprotective Products Market: Market Share (%) by Region, 2022
For More Details On this report - Request For Sample
Neuroprotective Products Market Segment Analysis - by Medical Condition
The Neuroprotective Products Market based on medical condition can be further segmented into Alzheimer’s Disease, Parkinson’s Disease, Spinal Cord Injury, Stroke and Others. The Alzheimer’s Disease Segment held the largest share of the Neuroprotective Products market in 2022. This growth is driven by the increasing predominance of Alzheimer’s Disease across the world. Cholinesterase inhibitors are drug classes utilized for the symptomatic treatment of Alzheimer’s Disease. The rising cases of Down’s Syndrome and head injuries are further propelling the growth of the Alzheimer’s Disease segment.
Furthermore, the Parkinson’s Disease segment is estimated to grow at the fastest CAGR of 7.3% during the forecast period 2023-2028. This growth can be attributed to the soaring application of neuromodulation devices to assist patients enduring Parkinson’s Disease, specifically those who do not respond well to medicines together with neuromodulation devices involving physical, occupational and speech therapies.
Neuroprotective Products Market Segment Analysis - by Drug Class
The Neuroprotective Products Market based on drug class can be further segmented into Cholinesterase Inhibitors, NMDA Receptor Antagonists, Neurotropic Factors, Metal Ion Chelators, Ion Channel Modulators and Others. The Cholinesterase Inhibitors segment held the largest share of the Neuroprotective Products market in 2022. This growth is fueled by the growing application of Cholinesterase Inhibitors for the treatment of Alzheimer’s Disease. Cholinesterase inhibitors obstruct the activity of the enzyme cholinesterase, which is accountable for breaking down acetylcholine. The increasing spending on R&D activities is further propelling the growth of this segment.
Furthermore, the Metal Ion Chelators segment is estimated to grow at the fastest CAGR of 7.5% during the forecast period 2023-2028. Various investigations have offered proof that metal ions are crucially involved in the pathogenesis of principal neurological ailments like Alzheimer’s Disease and Parkinson’s Disease.
Neuroprotective Products Market Segment Analysis - by Geography
Europe (Neuroprotective Products Market) dominated the largest Neuroprotective Products market with a 38% share of the overall market in 2022. The growth of this region is fueled by the increasing pervasiveness of neurological ailments requiring neurotropic factors in the European region. The growing initiatives by public and private organizations to boost awareness are further propelling the growth of the Neuroprotective Products Industry, thereby contributing to the Neuroprotective Products Industry Outlook, in the European region.
Furthermore, the Asia-Pacific region is estimated to be the region with the fastest CAGR over the forecast period 2023-2028. This growth is driven by factors like accelerated growth attributed to healthcare spending in the Asia-Pacific region. The major significance of neurotropic factors is further fueling the progress of the Neuroprotective Products Market in the Asia-Pacific region.
Neuroprotective Products Market Drivers
Surging Applications of Metal Ion Chelators:
As per World Health Organization (WHO), global estimates in 2019 demonstrated over 8.5 million people with Parkinson's Disease. Metal ion chelators have been recommended as possible therapies for ailments involving metal ion imbalance. Neurodegeneration is a superior target for performing the metal chelator technique in therapeutics. In contrast to the direct chelation technique in metal ion overload ailments, in neurodegeneration, the goal appears to be a superior and subtle modulation of metal ion homeostasis, intended towards restoring ionic balance. A range of 8-hydroxyquinoline equivalents demonstrated the largest potential for the treatment of neurodegenerative diseases. The surging applications of metal ion chelators are therefore fueling the growth of the Neuroprotective Products Market during the forecast period 2023-2028.
Soaring Significance of Ion Channel Modulators:
As per World Health Organization (WHO), more than 50 million people globally have epilepsy. A channel modulator or ion channel modulator is a kind of medication that modulates ion channels. Ion channels are usually classified by gating mechanism and by the ion they transport. It may be noticed that an ion channel may overlap between different categories. Ion channel function or dysfunction serves a vital role in neurological and neurodegenerative conditions like chronic pain, motor disorders, epilepsy, Parkinson’s, Huntington’s and Alzheimer’s disease, Amyotrophic lateral sclerosis and schizophrenia. The soaring significance of Ion Channel Modulators is therefore driving the growth of the Neuroprotective Products Industry, thereby contributing to the Neuroprotective Products Industry Outlook during the forecast period 2023-2028.
Neuroprotective Products Market Challenges
Issues with Natural Products for Alzheimer’s Disease:
As per Alzheimer’s Association website, COVID-19 added a 17% increase in Alzheimer’s and dementia demises in 2020. Certain disadvantages and challenges associated with natural products and their isolated natural compounds include physicochemical instability, restricted water solubility, accelerated metabolism, low bioavailability and distribution to the Central Nervous System (CNS). These challenges may influence the clinical efficiency of those products in Alzheimer’s Disease treatment. The existence of the blood-brain barrier needs adequate lipophilicity from natural products to be able to permeate the CNS. This may create extra obstacles for certain neuroprotective natural products, inclusive of polyphenols and polysaccharides and restrict their clinical efficiency. These issues are thus hampering the growth of the Neuroprotective Products Market.
Neuroprotective Products Industry Outlook
Product launches, product approvals, patents, events, acquisitions, partnerships, collaborations and R&D activities are key strategies adopted by players in the Neuroprotective Products Market. The top 10 companies in the Neuroprotective Products market are:
- Genervon Biopharmaceuticals
- NeuroVive Pharmaceutical
- Neuren Pharmaceuticals
- Allon therapeutics
- Bionure Inc.
- F. Hoffmann-La Roche AG
- Eli Lilly and Company
- Daiichi Sankyo Company
- In November 2021, Roche declared the introduction of the cobas® 5800 System. This is a novel molecular laboratory instrument.
- In April 2021, Roche declared a range of five novel intended applications. This was performed for two essential cardiac biomarkers utilizing the Elecsys® technology. They are highly sensitive cardiac troponin T (cTnT-hs) and N-terminal pro-brain natriuretic peptide test (NT-proBNP).
- In January 2021, Roche declared the CE-IVD introduction of its automated digital pathology algorithms. They are uPath HER2 (4B5) image analysis and uPath Dual ISH Image analysis for breast cancer. This assists in deciding the best treatment strategy for every patient.